PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1424962
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1424962
Clinical Trial Biorepository & Archiving Solutions Market Size and Share Report by Product, Phase, Offering - Global Industry Demand Forecast to 2030
In 2023, the global clinical trial biorepository & archiving solutions market generated revenue of USD 3,985.2 million, which is expected to grow at a compound annual growth rate of 8.2% to reach USD 6,916.6 million by 2030.
This growth of the market can be credited to the rising count of companies offering an extensive variety of services and the growing trend of outsourcing storage and other cold-chain processes so that the essential resources can concentrate more on medicinal development.
Furthermore, storage and transport techs are constantly advancing, which, combined with the l regulatory needs on bio-storage and the present trends in this space, can enormously help in saving money, time, and effort.
The clinical trial biorepository & archiving solutions industry is rising quickly because of the improvement in the obtainability of less expensive devices to compile data, for streamline reporting, using software that provides the functionality of a combined laboratory information management system made to aid in managing laboratory samples and information.
Furthermore, multifaceted data is created during trials, and the managing of such information and all the biorepository procedures makes such software essential, therefore creating an opportunity for the providers of archiving solutions.
On the basis of phase, the phase III category accounted for the largest revenue share, of 45%, in 2023, and it is further expected to maintain its dominance in the future. It is due to the fact that a significant number of specimens and samples are used by Phase III studies for long-term research, leading to increased demand for biorepository and archive solutions from clinical trials.
In phase III of the clinical trial process, researchers and scientists will evaluate the efficacy and safety of novel treatments. The number of patients participating for a long time is very high among the majority of phase III clinical studies. Besides that, because of the high number of people involved for a long time, this stage is more likely to be affected by short- and long-term side effects.
In 2023, the North American region dominated the clinical trial biorepository & archiving solutions market with the largest share of 55%, and the region is also estimated to continue with the dominance in the future. This is mainly because of the rising number of clinical trials, the presence of global market leaders, and the usage of progressive techs in the region. Furthermore, the presence of a huge count of service providers, CROs, and biopharmaceutical businesses enhances the market growth potential.
Hence, this growth of the market can be credited to the rising count of companies offering an extensive variety of services and the growing trend of the outsourcing of storage and other cold-chain processes, so that the essential resources can concentrate more on medicinal development.
Top Providers of Clinical Trial Biorepository & Archiving Solutions Are:
Azenta US Inc.
Thermo Fisher Scientific Inc.
Precision Medicine Group LLC
Medpace Inc.
Labcorp Drug Development
American Type Culture Collection
IQVIA Inc.
LabConnect Inc.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by product
- 1.4.2. Market size breakdown, by phase
- 1.4.3. Market size breakdown, by offering
- 1.4.4. Market size breakdown, by region
- 1.4.5. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Product (2017-2030)
- 6.3. Market Revenue, by Phase (2017-2030)
- 6.4. Market Revenue, by Offering (2017-2030)
- 6.5. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Product (2017-2030)
- 7.3. Market Revenue, by Phase (2017-2030)
- 7.4. Market Revenue, by Offering (2017-2030)
- 7.5. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Product (2017-2030)
- 8.3. Market Revenue, by Phase (2017-2030)
- 8.4. Market Revenue, by Offering (2017-2030)
- 8.5. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Product (2017-2030)
- 9.3. Market Revenue, by Phase (2017-2030)
- 9.4. Market Revenue, by Offering (2017-2030)
- 9.5. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Product (2017-2030)
- 10.3. Market Revenue, by Phase (2017-2030)
- 10.4. Market Revenue, by Offering (2017-2030)
- 10.5. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Product (2017-2030)
- 11.3. Market Revenue, by Phase (2017-2030)
- 11.4. Market Revenue, by Offering (2017-2030)
- 11.5. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Product (2017-2030)
- 12.3. Market Revenue, by Phase (2017-2030)
- 12.4. Market Revenue, by Offering (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Product (2017-2030)
- 13.3. Market Revenue, by Phase (2017-2030)
- 13.4. Market Revenue, by Offering (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Product (2017-2030)
- 14.3. Market Revenue, by Phase (2017-2030)
- 14.4. Market Revenue, by Offering (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Product (2017-2030)
- 15.3. Market Revenue, by Phase (2017-2030)
- 15.4. Market Revenue, by Offering (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Product (2017-2030)
- 16.3. Market Revenue, by Phase (2017-2030)
- 16.4. Market Revenue, by Offering (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Product (2017-2030)
- 17.3. Market Revenue, by Phase (2017-2030)
- 17.4. Market Revenue, by Offering (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Product (2017-2030)
- 18.3. Market Revenue, by Phase (2017-2030)
- 18.4. Market Revenue, by Offering (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Product (2017-2030)
- 19.3. Market Revenue, by Phase (2017-2030)
- 19.4. Market Revenue, by Offering (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Product (2017-2030)
- 20.3. Market Revenue, by Phase (2017-2030)
- 20.4. Market Revenue, by Offering (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Product (2017-2030)
- 21.3. Market Revenue, by Phase (2017-2030)
- 21.4. Market Revenue, by Offering (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Product (2017-2030)
- 22.3. Market Revenue, by Phase (2017-2030)
- 22.4. Market Revenue, by Offering (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Product (2017-2030)
- 23.3. Market Revenue, by Phase (2017-2030)
- 23.4. Market Revenue, by Offering (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Product (2017-2030)
- 24.3. Market Revenue, by Phase (2017-2030)
- 24.4. Market Revenue, by Offering (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Product (2017-2030)
- 25.3. Market Revenue, by Phase (2017-2030)
- 25.4. Market Revenue, by Offering (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Product (2017-2030)
- 26.3. Market Revenue, by Phase (2017-2030)
- 26.4. Market Revenue, by Offering (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Product (2017-2030)
- 27.3. Market Revenue, by Phase (2017-2030)
- 27.4. Market Revenue, by Offering (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Product (2017-2030)
- 28.3. Market Revenue, by Phase (2017-2030)
- 28.4. Market Revenue, by Offering (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Azenta Life Sciences
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. Thermo Fisher Scientific Inc.
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Precision Medicine Group LLC
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. Medpace Inc.
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. Labcorp Drug Development
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. American Type Culture Collection
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. IQVIA Inc.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. LabConnect Inc.
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
